25 completed, 9 terminated, 6 withdrawn, 2 unknown. 44 Phase 2, 8 Phase 1, 4 Phase 3.
Follow Inhalation: new trials by email Literature Review of Inhalation trials Research Report on Inhalation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 240 | 2024-09-14 | 2025-04-11 |
| A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease HRG2005 inhalation, Placebo to match HRG2005 inhalation, Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 82 | 2024-01-15 | 2025-12-22 |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 75 | 2023-08-23 | 2025-04-17 |
| Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer CIS-DPI - NSCLC (advanced Non-small Cell Lung Cancer), Stage IV Lung Cancer | Phase 1 / Phase 2 | Recruiting | Inhatarget Therapeutics | 32 | 2023-06-23 | 2025-03-26 |
| Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 FB2001, FB2001 placebo - Mild to Moderate COVID-19 | Phase 2 / Phase 3 | Unknown | Frontier Biotechnologies Inc. | 1336 | 2023-01-04 | 2023-01-09 |
| A Phase II Clinical Trial of TQC3721 Suspension for Inhalation TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 59 | 2022-05-20 | 2025-04-20 |
| Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years. 1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for booster groups - COVID-19 | Phase 2 | Unknown | Seventh Medical Center of PLA General Hospital | 410 | 2022-04-17 | 2023-04-13 |
| Nitrous Oxide as Treatment for Fibromyalgia Nitrous oxide gas for inhalation, Placebo - Fibromyalgia, Central Neuropathic Pain | Phase 2 | Withdrawn | University of Chicago | 2021-11-12 | 2026-05-14 | |
| Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms Drug, inhalation - Covid19 | Phase 2 | Terminated | Aquilon Pharmaceuticals S.A. | 21 | 2021-11-04 | 2023-01-06 |
| A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis OligoG Dry powder for inhalation - Cystic Fibrosis | Phase 2 / Phase 3 | Withdrawn | AlgiPharma AS | 2021-09-01 | 2022-06-30 | |
| Antidepressant Effects of Nitrous Oxide Nitrous oxide gas for inhalation, Placebo - Major Depressive Disorder, Treatment Resistant Depression | Phase 2 | Withdrawn | University of Chicago | 2021-06-30 | 2026-05-14 | |
| Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women Nitrous oxide gas for inhalation, Oxygen Gas for Inhalation - Contraceptive Devices, Long-Acting Reversible Contraception | Phase 2 / Phase 3 | Withdrawn | Boston Children's Hospital | 2021-06-01 | 2022-09-16 | |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation - COVID-19 | Phase 1 / Phase 2 | Completed | CanSino Biologics Inc. | 840 | 2021-04-21 | 2023-02-08 |
| Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 N-Acetyl cysteine, Placebo - Neurofibromatosis 1 | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 25 | 2021-02-23 | 2026-06-05 |
| Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients. AMOR 18 Powder & Inhalation, Placebo - Covid19 | Phase 1 / Phase 2 | Completed | Amorphical Ltd. | 66 | 2021-02-09 | 2024-02-28 |
| A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age Lucinactant for Inhalation, nCPAP Only - Respiratory Distress Syndrome, Newborn | Phase 2 | Terminated | Windtree Therapeutics | 12 | 2020-04-18 | 2023-05-24 |
| Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients Nitrogen Gas for Inhalation, Blood withdrawal, Nitric Oxide - Cardiovascular Diseases, Oxidative Stress | Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-07-25 | 2025-12-02 | |
| Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 N-acetylcysteine (NAC), Placebo - Neurofibromatosis 1 | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 5 | 2019-01-15 | 2026-04-21 |
Showing 20 of 44. Sign in to see all of them.
Cystic Fibrosis (8) · Pulmonary Disease, Chronic Obstructive (7) · COVID-19 (5) · Lung Diseases (3) · Pseudomonas Infections (3) · Respiratory Distress Syndrome (3) · Respiratory Tract Infections (3) · Alzheimer Disease 5 (2) · Asthma (2) · Coronavirus Infections (2) · Depression (2) · Depressive Disorder, Major (2) · Depressive Disorder, Treatment-Resistant (2) · Mycobacterium Infections, Nontuberculous (2) · Neurofibromatosis 1 (2)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Insmed Incorporated (3) · University of Chicago (3) · Windtree Therapeutics (3) · Children's Hospital Medical Center, Cincinnati (2) · Kamada, Ltd. (2) · Mallinckrodt (2) · AlgiPharma AS (1) · Amorphical Ltd. (1) · Amphastar Pharmaceuticals, Inc. (1) · Apeptico Forschung und Entwicklung GmbH (1) · Aquilon Pharmaceuticals S.A. (1) · Aradigm Corporation (1) · BDD Pharma Ltd (1) · Boehringer Ingelheim (1)
United States (21) · China (7) · United Kingdom (7) · Canada (5) · Germany (4) · Poland (4) · Belgium (3) · Hungary (2) · Serbia (2) · Ukraine (2) · Australia (1) · Austria (1) · Bulgaria (1) · Chile (1) · Denmark (1)
Peter Nagele, MD, MSc (3) · George Retsch-Bogart, MD (2) · Gina Eagle, MD (2) · Anne Munck, Dr (1) · Bonnie W. Ramsey (1) · Carlos Guardia, MD (1) · Chen Dong (1) · Cheng Yao (1) · Christiane De Boeck (1) · David Waltz, M.D. (1) · Donald Gilbert, MD MS (1) · Donald L Gilbert, MD, MS (1) · Edward Kerwin, MD (1)
PMID 19183804, PMID 21893650, PMID 25972024, PMID 26288390, PMID 27748623, PMID 31467115, PMID 32050447, PMID 32423275, PMID 33595792, PMID 33709856, PMID 36996759, PMID 37202147, PMID 37209700, PMID 38543926, PMID 41812987
2018 (1), M01RR000037 (1), R01DK057755 (1), R44HL107000 (1), U01HL080310 (1)